Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Ontology highlight
ABSTRACT: Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study. Subjects will automatically enroll into study FT-003 once they have withdrawn or complete the parent interventional study.
The purpose of this study is to provide long-term safety and survival data for subjects who have participated in the parent study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study.
DISEASE(S): Microsatellite Instability,Carcinoma,Cervical Cancer,Melanoma,Colorectal Cancer,Small Cell Lung Carcinoma,Egfr Positive Solid Tumor,Urothelial Carcinoma,Merkel Cell Carcinoma,Carcinoma, Merkel Cell,Lymphoma,Pancreas Cancer,Nsclc,Gastric Cancer,Advanced Solid Tumor,Squamous Cell Carcinoma,Carcinoma, Renal Cell,Head And Neck Cancer,Her2-positive Breast Cancer,Small-cell Lung Cancer,Renal Cell Carcinoma,Pancreatic Neoplasms,Hepatocellular Carcinoma
PROVIDER: 2317553 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA